TRT and HGH coaching claims: what the evidence actually says
Quick answer
The video describes a post-trenbolone blood work scenario with polycythemia (hematocrit 56%), severely suppressed HDL (22 mg/dL), elevated LDL, hepatotoxicity markers, stage 1 or 2 hypertension, and hyperprolactinemia. These are not mild findings; they represent overlapping cardiovascular, hepatic, and endocrine risks that warrant physician evaluation rather than a self-directed supplement and peptide protocol. Several interventions named, including telmisartan and cabergoline, are prescription drugs requiring diagnosis and monitoring before use.
Our take · Written by FormBlends editorial team · Reviewed by FormBlends Medical Team· This is not a transcript. It is our independent review of the video above.
What did @coach.agz actually say?
The creator laid out a post-trenbolone blood work recovery protocol targeting hematocrit at 56%, HDL at 22, LDL near 180, elevated liver enzymes, borderline hypertension, and rising prolactin. The plan includes blood donation, telmisartan, TUDCA, NAC, injectable glutathione, reduced testosterone, omega-3s, zone 2 cardio, cabergoline, and peptides BPC-157 and TB-500, with a 30-to-40-day timeline for normalization.
To be fair, the creator does not claim to be a physician. But the video is structured as actionable medical advice with specific dosing, specific drugs, and specific timelines. That framing matters when the audience is running compounds they likely acquired outside a clinical setting. The "comment health for my free protocol" outro is a lead-generation mechanic, not a disclaimer.
Does the science back this up?
Parts of it do, parts of it are plausible but overstated, and at least one recommendation is based almost entirely on anecdote. The zone 2 cardio claim for HDL recovery is the strongest evidence-based element here. The peptide claims are the weakest.
Zone 2 aerobic training genuinely raises HDL. A meta-analysis by Kodama et al. (2007, JAMA) found aerobic exercise increased HDL-C by roughly 2.53 mg/dL on average, with greater effect at higher weekly caloric expenditure from exercise. Four sessions at 45 minutes is a reasonable starting point, though HDL recovery after anabolic steroid suppression can take months, not weeks.
Omega-3s at high doses do have lipid effects, primarily on triglycerides. The evidence for omega-3s directly raising HDL is modest at best. A 2019 Cochrane review found omega-3 supplementation had little to no effect on HDL. The creator calls this "your primary lipid prevention," which overstates what the literature actually supports.
TUDCA has legitimate hepatoprotective data in cholestatic liver disease (Leuschner et al., 1999, Digestion), and NAC has antioxidant support for liver stress. Telmisartan is an ARB with solid antihypertensive and some endothelial-protective data. These are reasonable inclusions. BPC-157 and TB-500 have no robust human clinical trial data for systemic inflammation reduction. Claiming they reduce systemic inflammatory markers is not supported by available evidence.
What did they get wrong (or right)?
They got the urgency right. Hematocrit above 55% is a real cardiovascular risk, and the creator correctly identifies this as the first thing to address. Blood donation is a legitimate acute intervention. That part checks out.
They got cabergoline basically right for elevated prolactin, though the framing as a one-size solution glosses over the fact that prolactin elevation in this context requires a baseline measurement and ideally a physician's interpretation before dosing any dopamine agonist.
The bigger problem is the timeline. "Your hematocrit should be normalized" and "HDL recovering" within 30 to 40 days is optimistic to the point of being misleading. HDL suppression from 19-nortestosterone derivatives like trenbolone can persist for months post-cycle (Hartgens and Kuipers, 2004, Sports Medicine). Telling someone their HDL will recover in a month from omega-3s and cardio sets an expectation the evidence does not support.
The injectable glutathione recommendation is where the video loses clinical credibility. IV glutathione has limited peer-reviewed support for liver recovery in this context, and recommending it as a self-administered intervention without supervision is not appropriate guidance.
BPC-157 and TB-500 are research peptides with no approved human indication. Framing them as tools for "systemic inflammation reduction" is an unsupported claim that goes beyond what current evidence allows.
What should you actually know?
If your blood work looks like what this video describes after a trenbolone cycle, you need a physician, not a TikTok protocol. Several of the drugs mentioned, including telmisartan and cabergoline, are prescription medications. Running them without a diagnosis and a monitoring plan is not optimization, it is self-medicating serious cardiovascular and endocrine findings.
The creator is not wrong that lifestyle changes, reduced compound load, and targeted supplementation can move markers in the right direction. But the 30-to-40-day normalization claim is almost certainly underselling how long actual recovery takes, particularly for lipids. Research consistently shows HDL suppression from anabolic steroids can take six months or longer to resolve (Hartgens and Kuipers, 2004).
The "free 60-day protocol" offer is a lead-generation funnel. That does not make the advice automatically wrong, but it does mean the person sending it to you has a commercial incentive. Any protocol involving prescription drugs and injectable peptides should be reviewed by a licensed clinician who can actually see your full panel, your history, and your medications. No TikTok comment thread replaces that.
Video review standard
Clinical fact-check snapshot
FormBlends treats social health videos as a starting point, then checks the claim against medical context, source quality, safety limits, and whether licensed provider review belongs in the next step.
Evidence signal
Source-backed review
Regulatory reality
Access rules depend on the compound and patient situation
Safety screen
Viral claims can miss contraindications, dose escalation, medication interactions, and quality-control risks.
This page currently connects to 9 source-backed evidence items through visible references or structured citation data.
PubMed evidence trail
Research sources used to frame this page
For TRT and HGH coaching claims: what the evidence actually says, FormBlends checks the page topic against primary trials, systematic reviews, guidelines, and current PubMed-indexed literature where available. These citations are context, not medical advice, proof of eligibility, or a claim that every study applies to every patient.
Multifunctionality and Possible Medical Application of the BPC 157 Peptide
Used to frame BPC-157 as an investigational peptide with mixed preclinical and limited human evidence.
PubMed
Gastric pentadecapeptide BPC 157 and its role in accelerating musculoskeletal soft tissue healing
Supports cautious tissue-repair context without presenting BPC-157 as an approved therapy.
PubMed
beta-Thymosins
Background source for thymosin biology and tissue-repair mechanisms.
PubMed
Thymosin beta 4 and the eye: the journey from bench to bedside
Shows how thymosin beta-4 evidence differs by route, tissue, and clinical application.
PubMed
Video claim decision path
Turn the claim into a safer next question
Direct answer
TRT and HGH coaching claims: what the evidence actually says should be treated as a claim to verify, then compared with evidence, safety context, and a provider review path.
Evidence check
Social clips are useful prompts, but they rarely show the full evidence base, contraindications, or dosing context.
Safety check
A viral claim can miss patient-specific risks, medication interactions, legal access, and source quality.
Next step
Use the health tools and supporting evidence to prepare questions for your clinician.
Claim path
Keep researching this testosterone and trt video claims cluster
Best for searchers turning TRT social claims into a safer lab-backed provider discussion.
Claim verdict
The useful answer behind this video
Claim being checked
The video describes a post-trenbolone blood work scenario with polycythemia (hematocrit 56%), severely suppressed HDL (22 mg/dL), elevated LDL, hepatotoxicity markers, stage 1 or 2 hypertension, and hyperprolactinemia.
FormBlends verdict
The video describes a post-trenbolone blood work scenario with polycythemia (hematocrit 56%), severely suppressed HDL (22 mg/dL), elevated LDL, hepatotoxicity markers, stage 1 or 2 hypertension, and hyperprolactinemia. These are not mild findings; they represent overlapping cardiovascular, hepatic, and endocrine risks that warrant physician evaluation rather than a self-directed supplement and peptide protocol. Several interventions named, including telmisartan and cabergoline, are prescription drugs requiring diagnosis and monitoring before use.
Patient-safe next step
Compare the claim with FormBlends safety guidance and a licensed-provider review before acting.
What to do with this video
Use the clip as a claim to verify, not a treatment plan
What it helps with
- The video describes a post-trenbolone blood work scenario with polycythemia (hematocrit 56%), severely suppressed HDL (22 mg/dL), elevated LDL, hepatotoxicity markers, stage 1 or 2 hypertension, and hyperprolactinemia. These are not mild findings; they represent overlapping cardiovascular, hepatic, and endocrine risks that warrant physician evaluation rather than a self-directed supplement and peptide protocol. Several interventions named, including telmisartan and cabergoline, are prescription drugs requiring diagnosis and monitoring before use.
- Hematocrit above 54-55% is a recognized threshold for cardiovascular risk in testosterone therapy guidelines (Bhasin et al., 2018, NEJM); phlebotomy is a legitimate acute tool but should be done with physician oversight, not solely based on a social media protocol.
- A 2007 JAMA meta-analysis (Kodama et al.) found aerobic exercise raises HDL by roughly 2.5 mg/dL on average; four sessions of zone 2 cardio per week is a reasonable starting point but will not normalize severely suppressed HDL in 30 days.
What it may miss
- It may not cover eligibility, contraindications, medication interactions, lab history, or dose escalation.
- Compound access, legal status, and product quality still need a separate safety check.
- Social video captions rarely show the full evidence base behind a claim.
Best next step
Compare the claim against a FormBlends guide, safety page, and licensed-provider review before acting.
Start provider reviewWhat You'll Learn
- Hematocrit above 54-55% is a recognized threshold for cardiovascular risk in testosterone therapy guidelines (Bhasin et al., 2018, NEJM); phlebotomy is a legitimate acute tool but should be done with physician oversight, not solely based on a social media protocol.
- A 2007 JAMA meta-analysis (Kodama et al.) found aerobic exercise raises HDL by roughly 2.5 mg/dL on average; four sessions of zone 2 cardio per week is a reasonable starting point but will not normalize severely suppressed HDL in 30 days.
- Omega-3 supplementation has strong evidence for lowering triglycerides, but a 2019 Cochrane review found minimal effect on HDL-C, directly contradicting the claim that omega-3s are the primary lipid recovery intervention.
- HDL suppression from anabolic-androgenic steroids, particularly 19-nortestosterone compounds like trenbolone, can persist for six months or more after cessation (Hartgens and Kuipers, 2004, Sports Medicine); a 30-to-40-day recovery timeline is not well-supported.
- Telmisartan and cabergoline are prescription drugs. Using either without a physician's diagnosis and a monitoring plan carries real risk, including hypotension from telmisartan and cardiac valve concerns with long-term dopamine agonist use.
- BPC-157 and TB-500 have no approved human indications and no peer-reviewed clinical trial data supporting systemic anti-inflammatory effects in humans; their inclusion in a recovery protocol as though they are established interventions is not supported by current evidence.
- TUDCA has legitimate hepatoprotective data in cholestatic liver disease contexts (Leuschner et al., 1999, Digestion), and NAC has antioxidant liver support data; these are among the more evidence-grounded supplement recommendations in the video.
Interested in GLP-1 or peptide therapy?
Get matched with licensed-provider review to help decide if it is right for you.
About the Creator
coach.agz · TikTok creator
26.1K views on this video
Link in bio for 1:1 coaching #testosterone #bodybuilding #trt #hgh
Sources & references
Citations extracted from our medical team's review. Click any citation to search PubMed.
Read More on This Topic
Our written guides go deeper with dosing details, comparison tables, and medical-team reviewed protocols.
Not medical advice. This video was made by coach.agz, not by FormBlends. Our write-up above is an editorial review, not a medical recommendation. Talk to your doctor before making any decisions about medications or treatments.